Native and Aspirin-Triggered Lipoxins Control Innate Immunity by Inducing Proteasomal Degradation of TRAF6

DSpace/Manakin Repository

Native and Aspirin-Triggered Lipoxins Control Innate Immunity by Inducing Proteasomal Degradation of TRAF6

Citable link to this page

 

 
Title: Native and Aspirin-Triggered Lipoxins Control Innate Immunity by Inducing Proteasomal Degradation of TRAF6
Author: Machado, Fabiana S.; Esper, Lísia; Dias, Alexandra; Madan, Rajat; Gu, YuanYuan; Hildeman, David; Karp, Christopher L.; Aliberti, Júlio; Serhan, Charles Nicholas

Note: Order does not necessarily reflect citation order of authors.

Citation: Machado, Fabiana S., Lísia Esper, Alexandra Dias, Rajat Madan, YuanYuan Gu, David Hildeman, Charles N. Serhan, Christopher L. Karp, and Júlio Aliberti. 2008. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. The Journal of Experimental Medicine 205(5): 1077-1086.
Full Text & Related Files:
Abstract: Innate immune signaling is critical for the development of protective immunity. Such signaling is, perforce, tightly controlled. Lipoxins (LXs) are eicosanoid mediators that play key counterregulatory roles during infection. The molecular mechanisms underlying LX-mediated control of innate immune signaling are of interest. In this study, we show that LX and aspirin (ASA)-triggered LX (ATL) inhibit innate immune signaling by inducing suppressor of cytokine signaling (SOCS) 2–dependent ubiquitinylation and proteasome-mediated degradation of TNF receptor–associated factor (TRAF) 2 and TRAF6, which are adaptor molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members to intracellular signaling events. LX-mediated degradation of TRAF6 inhibits proinflammatory cytokine production by dendritic cells. This restraint of innate immune signaling can be ablated by inhibition of proteasome function. In vivo, this leads to dysregulated immune responses, accompanied by increased mortality during infection. Proteasomal degradation of TRAF6 is a central mechanism underlying LX-driven immune counterregulation, and a hitherto unappreciated mechanism of action of ASA. These findings suggest a new molecular target for drug development for diseases marked by dysregulated inflammatory responses.
Published Version: doi://10.1084/jem.20072416
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2373840/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10140326
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters